Key Points
- Insider sale: Director Anil Ranganath sold 3,000 shares on Nov. 25 at an average of $145.22 for total proceeds of $435,660, reducing his holdings to 13,955 shares (a ~17.7% decrease).
- Strong quarter: TransMedics reported $0.66 EPS vs. a $0.37 consensus and revenue up 32.2% YoY (revenues $143.82M, slightly below the $145.33M estimate).
- Analyst sentiment: The stock carries a MarketBeat average rating of "Moderate Buy" with seven Buy and five Hold ratings and an average price target of $131.80.
TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) insider Anil Ranganath sold 3,000 shares of the firm's stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $145.22, for a total transaction of $435,660.00. Following the completion of the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $2,026,545.10. The trade was a 17.69% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
TransMedics Group Stock Performance
Shares of TMDX opened at $145.75 on Thursday. The firm has a market capitalization of $4.98 billion, a P/E ratio of 59.01 and a beta of 2.05. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $148.50. The stock has a 50 day moving average price of $121.71 and a two-hundred day moving average price of $121.82. The company has a debt-to-equity ratio of 1.43, a quick ratio of 7.13 and a current ratio of 7.69.
TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.37 by $0.29. The business had revenue of $143.82 million during the quarter, compared to the consensus estimate of $145.33 million. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.TransMedics Group's revenue was up 32.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.12 earnings per share. TransMedics Group has set its FY 2025 guidance at EPS. Equities analysts forecast that TransMedics Group, Inc. will post 1 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on TMDX shares. Wall Street Zen raised shares of TransMedics Group from a "hold" rating to a "buy" rating in a research report on Saturday, October 18th. Morgan Stanley increased their price target on TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research report on Friday, August 1st. Stifel Nicolaus began coverage on TransMedics Group in a research note on Thursday, September 4th. They issued a "hold" rating and a $115.00 price objective for the company. Piper Sandler cut their price target on shares of TransMedics Group from $145.00 to $140.00 and set an "overweight" rating on the stock in a report on Thursday, October 30th. Finally, Canaccord Genuity Group increased their price target on shares of TransMedics Group from $142.00 to $147.00 and gave the company a "buy" rating in a research report on Thursday, October 30th. Seven investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $131.80.
Check Out Our Latest Report on TransMedics Group
Hedge Funds Weigh In On TransMedics Group
Several large investors have recently modified their holdings of the business. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of TransMedics Group by 244.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 3,113,082 shares of the company's stock valued at $209,448,000 after purchasing an additional 2,209,996 shares during the period. Marshall Wace LLP raised its holdings in TransMedics Group by 258.7% during the 2nd quarter. Marshall Wace LLP now owns 546,787 shares of the company's stock valued at $73,275,000 after acquiring an additional 394,340 shares during the period. Two Sigma Investments LP lifted its position in shares of TransMedics Group by 54.2% during the third quarter. Two Sigma Investments LP now owns 635,394 shares of the company's stock worth $71,291,000 after acquiring an additional 223,409 shares in the last quarter. Zevenbergen Capital Investments LLC boosted its holdings in shares of TransMedics Group by 112.7% in the third quarter. Zevenbergen Capital Investments LLC now owns 258,523 shares of the company's stock worth $29,006,000 after acquiring an additional 136,995 shares during the period. Finally, Capital Fund Management S.A. raised its stake in shares of TransMedics Group by 100.4% during the 1st quarter. Capital Fund Management S.A. now owns 252,294 shares of the company's stock valued at $16,974,000 after purchasing an additional 126,414 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.
TransMedics Group Company Profile
(
Get Free Report)
TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
